tag:blogger.com,1999:blog-4241416962008169508.post120957341800489323..comments2024-03-27T21:03:58.972-04:00Comments on Just A Life Sciences Blog...: Hospira Vs. Merck's Cubicin® (Daptomycin) Patent Appeal -- Argument Completed In July -- No Decision YetUnknownnoreply@blogger.comBlogger1125tag:blogger.com,1999:blog-4241416962008169508.post-84926532166927380502015-11-13T14:51:49.896-05:002015-11-13T14:51:49.896-05:00The Federal Circuit panel has made it clear that M...The Federal Circuit panel has made it clear that Merck will control Cubicin until at least September of 2016.<br /><br />In doing so, it sided with the federal District (trial level) court, and invalidated three of the four patents held by Cubist/Merck -- those reaching into 2019 -- for obviousness. But Wall Street was largely expecting this.<br /><br />Now the question is whether Merck will seek a rehearing <i>en banc</i>, or appeal to the US Supremes -- or let it go, and gear up for 2016 competition from Hospira -- now owned by Pfizer.<br /><br />We will let you know. I'll put the <a href="https://anewmerckreviewed.files.wordpress.com/2015/11/mrk-cubist-hosp-11-13-2015.pdf" rel="nofollow">full 32 page PDF of the opinion</a> in a new post, at some point, over the weekend.<br /><br />NamasteCondorhttp://shearlingsplowed.blogspot.comnoreply@blogger.com